ReP USP - Resultado da busca

Artigo de periodico
Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)
Spina, M.; Nagy, Z.; Ribera, J. M.; Federico, M.; Aurer, I.; Jordan, K.; Borsaru, G.; Pristupa, A. S.; Bosi, A.; Grosicki, S.; Glushko, N. L.; Ristic, D.; Jakucs, J.; Montesinos, P.; Mayer, J.; Rego, Eduardo Magalhães; Baldini, S.; Scartoni, S.; Capriati, A.; Maggi, C. A.; Simonelli, C.
Source: Annals of Oncology. Unidade: FMRP
Subjects: NEOPLASIAS, HEMATOLOGIA, RIM, ÁCIDO ÚRICO, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 28 abr. 2026.
APA
Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317
NLM
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2026 abr. 28 ] Available from: https://doi.org/10.1093/annonc/mdv317
Vancouver
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2026 abr. 28 ] Available from: https://doi.org/10.1093/annonc/mdv317
Trabalho de evento-resumo
Low post chemoradiotherapy plasma osteopontin level may be marker of clinical benefit in inoperable squamous cell head and neck carcinoma patients (2007)
Snitcovsky, I.; Bruniati, K.; Leitão, G.; Pasini, F.; Federico, M.; Castro, G.; Carreiro, K.; Campoflorito, C.; Villar, R.; Mangone, F.; Maistro, S.
Source: Abstracts. Conference titles: Oral Oncology Head and Neck Oncology & Pathology. Unidade: FM
Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO, CARCINOMA DE CÉLULAS ESCAMOSAS, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SNITCOVSKY, I. et al. Low post chemoradiotherapy plasma osteopontin level may be marker of clinical benefit in inoperable squamous cell head and neck carcinoma patients. 2007, Anais.. Amsterdam: Faculdade de Medicina, Universidade de São Paulo, 2007. p. 190. . Acesso em: 28 abr. 2026.
APA
Snitcovsky, I., Bruniati, K., Leitão, G., Pasini, F., Federico, M., Castro, G., et al. (2007). Low post chemoradiotherapy plasma osteopontin level may be marker of clinical benefit in inoperable squamous cell head and neck carcinoma patients. In Abstracts (p. 190). Amsterdam: Faculdade de Medicina, Universidade de São Paulo.
NLM
Snitcovsky I, Bruniati K, Leitão G, Pasini F, Federico M, Castro G, Carreiro K, Campoflorito C, Villar R, Mangone F, Maistro S. Low post chemoradiotherapy plasma osteopontin level may be marker of clinical benefit in inoperable squamous cell head and neck carcinoma patients. Abstracts. 2007 ; 190.[citado 2026 abr. 28 ]
Vancouver
Snitcovsky I, Bruniati K, Leitão G, Pasini F, Federico M, Castro G, Carreiro K, Campoflorito C, Villar R, Mangone F, Maistro S. Low post chemoradiotherapy plasma osteopontin level may be marker of clinical benefit in inoperable squamous cell head and neck carcinoma patients. Abstracts. 2007 ; 190.[citado 2026 abr. 28 ]
Trabalho de evento-resumo periodico
Defining guidelines on brca mutation testing at a medical oncology unit - at an university hospital in south-eastern Brazil (2006)
Brentani, A.; Diz, M. D. P. E.; Maistro, S.; Snitcovsky, I; Federico, M.
Source: Value in health. Conference titles: ISPOR Eleventh Annual International Meeting. Unidade: FM
Subjects: MUTAÇÃO GENÉTICA, NEOPLASIAS MAMÁRIAS (DIAGNÓTICO), FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRENTANI, A. et al. Defining guidelines on brca mutation testing at a medical oncology unit - at an university hospital in south-eastern Brazil. Value in health. Malden: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1111/j.1524-4733.2006.00102_2.x. Acesso em: 28 abr. 2026. , 2006
APA
Brentani, A., Diz, M. D. P. E., Maistro, S., Snitcovsky, I., & Federico, M. (2006). Defining guidelines on brca mutation testing at a medical oncology unit - at an university hospital in south-eastern Brazil. Value in health. Malden: Faculdade de Medicina, Universidade de São Paulo. doi:10.1111/j.1524-4733.2006.00102_2.x
NLM
Brentani A, Diz MDPE, Maistro S, Snitcovsky I, Federico M. Defining guidelines on brca mutation testing at a medical oncology unit - at an university hospital in south-eastern Brazil [Internet]. Value in health. 2006 ; 9( 3):[citado 2026 abr. 28 ] Available from: https://doi.org/10.1111/j.1524-4733.2006.00102_2.x
Vancouver
Brentani A, Diz MDPE, Maistro S, Snitcovsky I, Federico M. Defining guidelines on brca mutation testing at a medical oncology unit - at an university hospital in south-eastern Brazil [Internet]. Value in health. 2006 ; 9( 3):[citado 2026 abr. 28 ] Available from: https://doi.org/10.1111/j.1524-4733.2006.00102_2.x

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em

Non normalized affiliation

Countries of institutions of collaboration